We help eligible patients access Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults for as little as $69.95 per month through manufacturer Patient Assistance Programs.
The Aimovig Prescription Assistance Program is a manufacturer-sponsored initiative that provides Aimovig at no medication cost to qualifying patients who cannot afford it. The program is available to uninsured and underinsured U.S. residents who meet income and residency requirements. If approved,
you receive your medication at no cost.
AffordMyPrescriptions ensures cost never comes between you and migraine freedom. For a flat $69.95 per month, our Patient Advocates manage every step of your enrollment, from initial application through ongoing refills and annual re-enrollment.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$299 | Save ~$229/mo |
| CVS Pharmacy | ~$299 | Save ~$229/mo |
| Walmart | ~$299 | Save ~$229/mo |
| Costco | ~$310 | Save ~$240/mo |
| SingleCare (140mg) | ~$768 | Save ~$698/mo |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026.*
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management. Our $69.95/month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through Afford My Prescriptions is the better long–term solution:
Eligibility is generally determined by annual household income levels. Most programs follow guidelines that include a limit of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because these requirements can vary, we encourage you to contact Afford My Prescriptions directly so we can review your specific situation.
Aimovig (erenumab-aooe) is a once-monthly prescription self-injectable medication for the preventive treatment of migraine in adults. It is the first CGRP receptor antagonist antibody approved specifically for migraine prevention, available in 70 mg and 140 mg doses administered as a subcutaneous injection using a prefilled SureClick autoinjector or prefilled syringe.
How It Works:
During a migraine, your nervous system releases CGRP (calcitonin gene-related peptide), which binds to CGRP receptors in your brain, triggering blood vessel dilation, inflammation, and amplified pain signals. Aimovig specifically blocks the CGRP receptor — the docking station where CGRP binds to trigger migraine events — preventing the migraine cascade before it starts. As a monoclonal antibody, it stays active for weeks, providing continuous prevention from a single monthly injection.
Form and Use:
Self-injected once per month using a prefilled autoinjector or syringe into the thigh, abdomen, or upper arm. Most patients notice fewer migraine days within the first 1 to 3 months of treatment.
Generic Availability:
As of April 2026, no generic or biosimilar version of Aimovig is available. As a biologic, its equivalent would be a biosimilar. No biosimilar has received FDA approval, and development timelines remain uncertain.
Warnings:
May cause constipation (sometimes severe), high blood pressure, allergic reactions, and Raynaud’s phenomenon (circulation problems). Contact your healthcare provider if you experience severe or persistent symptoms.
The average retail price is approximately $676–$1,049/month. A cash-pay option brings the price to approximately $299/month. The manufacturer offers a $49/month copay card for commercially insured patients. Through AffordMyPrescriptions, qualifying patients receive Aimovig at no medication cost —our $69.95 monthly fee covers advocacy and program management.
All three are monthly injectable CGRP-targeting antibodies. Aimovig blocks the CGRP receptor (where CGRP docks), while Emgality and Ajovy block the CGRP molecule itself. In practice, all three have similar efficacy — the best choice depends on your insurance coverage and prescriber
recommendation.
Aimovig is an injectable antibody for migraine PREVENTION (taken monthly). Qulipta is a daily oral tablet also for prevention. Ubrelvy is an oral tablet for ACUTE treatment (taken when a migraine starts). Some patients use both a preventive and acute treatment.
Yes. Aimovig comes in prefilled SureClick autoinjectors designed for easy self-injection at home. Your healthcare provider will show you proper technique at your first visit.
Some patients notice fewer migraines within the first month, but full benefit may take 3 months to develop. Clinical guidelines recommend trying Aimovig for at least 3 months before determining effectiveness.
Our advocates explore every alternative — the $49 copay card, the $299/month cash-pay option, independent foundations, insurance appeals, and alternative CGRP preventive treatments such as Emgality, Ajovy, or Qulipta.
If you are struggling with the high cost of Aimovig, our team may be able to help you access
assistance programs designed to make medications more affordable. Check your eligibility
today and take the first step toward reducing your prescription costs.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.